Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
- 1 May 1995
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 15 (5), 678-682
- https://doi.org/10.1161/01.atv.15.5.678
Abstract
Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor under development. After completing an 8-week placebo-baseline dietary phase, 81 patients were randomly assigned to receive either placebo or 2.5, 5, 10, 20, 40, or 80 mg atorvastatin once daily for 6 weeks. Plasma LDL cholesterol reductions from baseline were dose related, with 25% to 61% reduction from the minimum dose to the maximum dose of 80 mg atorvastatin once a day. Plasma total cholesterol and apo B reductions were also dose related. Previously, reductions in LDL cholesterol of the magnitude observed in this study have been seen only with combination drug therapy. In this study, atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.Keywords
This publication has 8 references indexed in Scilit:
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)Jama-Journal Of The American Medical Association, 1993
- The discovery and development of HMG-CoA reductase inhibitors.Journal of Lipid Research, 1992
- ForewordCurrent Problems in Cardiology, 1992
- The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductaseTetrahedron Letters, 1992
- HMG CoA reductase inhibitorsCurrent Opinion in Lipidology, 1992
- New Horizons in Combination Drug Therapy for HypercholesterolemiaJMIR AI, 1989
- A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary HypercholesterolemiaJAMA, 1988
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert PanelArchives of Internal Medicine, 1988